News >

Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval

Jason Harris
Published: Tuesday, Nov 21, 2017

lung cancer
The FDA granted a priority review to durvalumab (Imfinzi) in October for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation.

“Although the overall survival data in this study have yet to mature, the clinically meaningful difference in progression-free survival merits consideration of durvalumab as a new standard of care in this patient population,” they wrote.

References

  1. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  2. Rizvi NA, Peters S. Immunotherapy for unresectable stage III non–small-cell lung cancer. N Engl J Med. 2017; 377:1986-1988.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x